ArticleEJNMMI research2017
Priming increases the anti-tumor effect and therapeutic window of
Article in EJNMMI research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 20 citations in OpenAlex.
- Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [BMC cancer · 2026Article
- Radiocopper in BCMA-targeted immunotheranostics of myeloma.Theranostics · 2026Article
- Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates.Frontiers in oncology · 2026Review
- Clinical significance of stratifying prostate cancer patients through specific circulating genes.Molecular oncology · 2025Article
- Comparison ofHeliyon · 2024Article
- Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors.European journal of nuclear medicine and molecular imaging · 2024Article
- The heterobivalent (SSTR2/albumin) radioligand [Theranostics · 2024Article
- Co-administration with A1M does not influence apoptotic response ofScientific reports · 2023Article
- Hyperfractionated Treatment withCancers · 2022Article
- Article
- Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer.Pharmaceutics · 2021Review
- Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.European journal of nuclear medicine and molecular imaging · 2020Review
- Recombinant αJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.Endocrine-related cancer · 2019Article
- Transcriptional effects ofEJNMMI research · 2019Article
- Multiparametric MR for non-invasive evaluation of tumour tissue histological characteristics after radionuclide therapy.NMR in biomedicine · 2019Article
- Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer.PloS one · 2019Article
- Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response toTranslational oncology · 2018Article
- The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.Endocrine-related cancer · 2018Article
- Hedgehog inhibitor sonidegib potentiatesBMC cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
resultsPriming resulted in a 1.9 times higher mean absorbed dose to the tumor tissue per administered activity, together with a reduced mean absorbed dose for kidneys. Priming gave the best overall anti-tumor effects. Magnetic resonance imaging showed no statistically significant difference in tumor response between treatment with and without priming. Gene expression analysis demonstrated effects on cell cycle regulation. Biological processes associated with apoptotic cell death were highly affected in the biodistribution and dosimetry study, via differential regulation of, e.g., APOE, BAX, CDKN1A, and GADD45A.
conclusionsPriming had the best overall anti-tumor effects and also resulted in an increased therapeutic window. Results indicate that potential biomarkers for tumor regrowth may be found in the p53 or JNK signaling pathways. Priming administration is an interesting optimization strategy for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.